K. George Chandy

Modulation of mouse Paneth cell alpha-defensin secretion by mIKCa1, a Ca2+-activated, intermediate conductance potassium channel.

Characterisation of the human voltage-gated potassium channel gene, KCNA7, a candidate gene for inherited cardiac disorders, and its exclusion as cause of progressive familial heart block I (PFHBI).

Mutating a critical lysine in ShK toxin alters its binding configuration in the pore-vestibule region of the voltage-gated potassium channel, Kv1.3.

A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes.

The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS.

Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis.

Potassium channels as therapeutic targets for autoimmune disorders.

SK3-1C, a dominant-negative suppressor of SKCa and IKCa channels.

International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels.

Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia.

SKCa channels mediate the medium but not the slow calcium-activated afterhyperpolarization in cortical neurons.

K+ channels as targets for specific immunomodulation.

Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators.

K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity.

Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.

The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain.

Potassium channels, memory T cells, and multiple sclerosis.

International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels.

International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels.

Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases.

The D-diastereomer of ShK toxin selectively blocks voltage-gated K+ channels and inhibits T lymphocyte proliferation.

The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans.

Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block.

Kv1.3 potassium channels as a therapeutic target in multiple sclerosis.

The functional network of ion channels in T lymphocytes.

Potassium channel modulation by a toxin domain in matrix metalloprotease 23.

Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis.

18F-Fallypride PET of pancreatic islets: in vitro and in vivo rodent studies.

Therapeutic potential of peptide toxins that target ion channels.

Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases.

Inhibitors of mitochondrial Kv1.3 channels induce Bax/Bak-independent death of cancer cells.

Kv1.3 deletion biases T cells toward an immunoregulatory phenotype and renders mice resistant to autoimmune encephalomyelitis.

Durable pharmacological responses from the peptide drug ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.

Modulation of voltage-gated K+ channels by the sodium channel β1 subunit.

Intracellular trafficking of the KV1.3 potassium channel is regulated by the prodomain of a matrix metalloprotease.

Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance.

Shaker-related potassium channels in the central medial nucleus of the thalamus are important molecular targets for arousal suppression by volatile general anesthetics.

Blockade of Kv1.3 channels ameliorates radiation-induced brain injury.

Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases.

Immunology: Channelling potassium to fight cancer.

International Union of Basic and Clinical Pharmacology. C. Nomenclature and Properties of Calcium-Activated and Sodium-Activated Potassium Channels.

Tissue resident memory T cells in the human conjunctiva and immune signatures in human dry eye disease.

Peptide blockers of Kv1.3 channels in T cells as therapeutics for autoimmune disease.